The increased CD155 expression on cancer cells leads to the proteasomal degradation of costimulatory receptor DNAM-1 on cytotoxic T cells, eventually resulting in the dysfunctional activity of CD8+ T cells in both human and mouse tumors [44]. Here, CD226 is linked to cancer.